The cytochrome P450-dependent monooxygenases constitute a superfamily of enzymes (30) that play a critical role in the oxidative metabolism of a wide variety of both endogenous (19, 28, 42) and exogenous (11) substances. In mammalian systems, the latter activity is restricted largely to enzymes belonging to families 1 through 4. Although some of these enzymes are constitutively expressed and noninducible, others are constitutively expressed and inducible, while still others are not constitutively expressed but inducible. CYP1A1 belongs to the latter group. Normally not expressed in adult tissues, CYP1A1 expression is induced severalfold upon exposure to a variety of xenobiotics, including halogenated hydrocarbons (e.g., dioxin) and polyaromatic hydrocarbons (e.g., benzo-[a]pyrene) (16) . Induction is mediated by the Ah receptor, a unique member of the basic helix-loop-helix family of transcription factors (31) . The function of CYP1A1 in cellular metabolism is unknown. However, the enzyme is highly active in the metabolism of polyaromatic hydrocarbon procarcinogens (e.g., benzo[a]pyrene) into their ultimate carcinogenic forms (3, 20) .
In a previous study (15) , we identified a 275-bp negative regulatory element (NRE) upstream of the human CYP1A1 coding region (Ϫ833 to Ϫ558). The deletion of this fragment resulted in an increase in both constitutive and inducible promoter activity. This observation led to the suggestion that mutations in the NRE or its binding protein may contribute to the large interindividual variation in human CYP1A1 inducibility (10) and to the aberrant expression noted in several lung carcinoma cell lines (26) and primary pulmonary carcinomas (27) . Similar mutations may well contribute to the highly inducible CYP1A1 phenotype that has been correlated with an increased incidence of lung cancer (21, 22) and to the moderate-to-high constitutive CYP1A1 activity correlated with a poor prognosis in human breast cancer (29, 34) .
We have characterized the human CYP1A1 NRE using both in vitro binding and transient-expression assays (6) . Subfragment analysis of the original 275-bp human NRE (15) demonstrated the presence of two functional elements. Both were capable of down-regulating a heterologous enhancer or promoter directing the expression of a reporter gene after transfection into the human hepatoma cell line HepG2. Further analysis of one of these elements revealed a DNase I footprint pattern consisting of three protected regions, a 21-bp palindrome sequence flanked by two distinct guanine-and cytosinerich elements. Employing transient expression studies, the CYP1A1 NRE Ϫ784 palindrome (Ϫ794 to Ϫ774) was shown to be capable of significant negative regulatory activity. In contrast, the guanine-and cytosine-rich sequences minus the palindrome had no such activity. However, these sequences may serve a secondary role, since all three elements appeared essential for optimum negative regulatory activity. Further, distinct DNase I hypersensitive sites indicative of potentially critical DNA conformational changes appear only when the guanine-and cytosine-rich sequences are bound. The second NRE element was shown to be dependent on a similar, though less well conserved, palindrome sequence with a point of symmetry at Ϫ573.
Given that the NRE Ϫ784 palindrome sequence alone is sufficient for negative regulatory activity, we have extended the previous studies exploring the interaction between specific nuclear proteins and components of the CYP1A1 NRE. We report that specific residues present in the Ϫ784 palindrome are critical for nuclear protein binding and negative regulatory activity. Employing competitive electrophoretic mobility shift assays (EMSA), we also introduce evidence for a protein immunologically related to NF-Y B interacting with the CYP1A1 NRE and rule out the involvement of several other known transcription factors.
MATERIALS AND METHODS
Materials. Antipain, aprotinin, leupeptin, pepstatin, phenylmethylsulfonyl fluoride, tissue culture medium, antibiotics, 4-methylumbelliferyl-␤-galactopyranoside, and 4-methylumbelliferone were purchased from Sigma Chemical Co. Fetal bovine serum was obtained from JRH Biosciences. Superscript reverse transcriptase and some restriction endonucleases were acquired from Life Technologies, Inc. Other restriction endonucleases and T4 polynucleotide kinase were obtained from New England Biolabs. T4 DNA polymerase, ␤-galactosidase and poly(dI-dC) were purchased from Boehringer Mannheim. Cells and culture conditions. Human HepG2 hepatoblastoma cells were a gift of B. Knowles (Jackson Laboratories) (1) . The cells were cultured in Eagle's minimal essential medium supplemented with 10% fetal bovine serum, 50 U of penicillin per ml, and 50 g of streptomycin per ml. Cell cultures were maintained in a humidified incubator at 37ЊC in an atmosphere of 5% CO 2 and 95% air.
Plasmid constructs. pRNH131 containing a 105-bp fragment (Ϫ833 to Ϫ728) from human CYP1A1 cloned into the SmaI site of pUC19 was described in a previous study (6) . This fragment includes the upstream NRE palindrome exhibiting a point of symmetry at Ϫ784. DNA oligonucleotides representing the sense and antisense strands of the three CYP1A1 NRE components previously identified by DNase I footprinting (6) were custom synthesized by National Biosciences, Inc. Complementary oligonucleotides were annealed by heating to 65ЊC and then slowly cooled to room temperature, phosphorylated with T4 polynucleotide kinase, and cloned into pUC19. pRNH209 consists of the 21-bp NRE palindrome sequence (Ϫ794 to Ϫ774) cloned into the SmaI site of pUC19. pRNH255 contains both guanine-and cytosine-rich regions (Ϫ818 to Ϫ798 and Ϫ767 to Ϫ749) cloned into the pUC19 multiple cloning site such that their relative orientation is the same as that found in CYP1A1, but they are separated by 22 bp of vector sequence rather than the CYP1A1 Ϫ784 palindrome.
For transient-expression assays, chloramphenicol acetyltransferase (CAT) expression was directed by the herpes simplex virus thymidine kinase (HSV tk) promoter and simian virus 40 (SV40) enhancer in the reporter plasmid pRNH195c (6) . The CAT reporter plasmid, pRNH220c, contains the human CYP1A1 NRE 105 fragment cloned immediately upstream of the SV40 enhancer and HSV tk promoter in pRNH195c and has been described previously (6) . pRNH483c was constructed in a fashion similar to that of pRNH220c but with the substitution of an NRE 105 fragment containing a guanine-to-thymine transversion at Ϫ787 (see below).
Site-directed mutagenesis of the CYP1A1 NRE Ϫ784 palindrome was performed by an oligonucleotide-directed mutagenesis system and pAlter vector (Promega) with modifications described in detail elsewhere (33) . The presence of the desired mutation(s) and the integrity of the remaining DNA fragment were verified by dideoxy sequencing (36) .
Plasmid DNA was used to transform E. coli SURE cells following the method of Hanahan (12) . The presence and orientation of inserts in the various plasmid constructs were verified by restriction endonuclease and DNA sequence analyses (36) .
EMSA. The preparation of HepG2 nuclear extract has been described previously (6) . Protein concentration was determined by the micro bicinchoninic acid protein assay (39) . EMSA probes NRE 105 , NRE21, and NRE57 were isolated from pRNH131, pRNH209, and pRNH255, respectively, by SacI-HindIII digestion. The NRE 105 probe consisted of a 150-bp fragment containing CYP1A1 sequences Ϫ833 to Ϫ728, the NRE21 probe consisted of a 65-bp fragment containing CYP1A1 sequences Ϫ794 to Ϫ774, and the NRE57 probe consisted of a 85-bp fragment containing CYP1A1 sequences Ϫ818 to Ϫ767 and Ϫ767 to Ϫ749 separated by 22 bp of vector sequence. Probes were radiolabeled with Superscript reverse transcriptase, and EMSA were performed as previously described (6) . Unlabeled, competing NRE 105 , NRE21, or NRE57 fragments were included in some of the incubations at a 10-to 100-fold molar excess over the labeled probes. In other experiments, a 25-to 1,000-fold molar excess of unlabeled consensus oligonucleotide was used to compete with the NRE 105 radiolabeled probe. In addition to the oligonucleotides representing transcription factor consensus binding sequences, NRE6 was used in these experiments. This was a 24-bp oligonucleotide representing CYP1A1 sequences Ϫ794 to Ϫ774 plus three additional bases to create a unique PmlI restriction endonuclease site on the 3Ј end.
For competitive EMSA, unlabeled 177-bp wild-type and mutated ApaIBpu1102 NRE fragments (CYP1A1 sequences Ϫ834 to Ϫ656) were used to compete for specific protein binding with the radiolabeled 177-bp wild-type probe at a 0-to 1,000-fold molar excess. Following overnight exposure, the autoradiographs were used as templates to excise the specific DNA-protein complexes from the gel. Dried gel slices were solubilized with Solvable (DuPont) and counted in scintillation cocktail as suggested by the manufacturer. Competition was expressed as the percentage of specific bound DNA-protein complex observed in the absence of competitor DNA.
EMSA supershift assays were performed essentially as described above, except nuclear extract was preincubated with antibody overnight at 4ЊC. One microliter of a monoclonal NF-Y A antibody raised against recombinant NF-Y A protein (YA1a), 0.5 l of a polyclonal antiserum raised against recombinant NF-Y B protein (pR␣YB), 0.5 l of preimmune rabbit serum, or 0.02 l of an affinitypurified pR␣YB antibody (affinity purified against recombinant NF-Y B ) was added to the nuclear extract. These antibodies have been extensively characterized by Mantovani and colleagues and are described elsewhere (25) .
Transient-expression assays. HepG2 cells were plated onto polylysine-treated 100-mm-diameter culture dishes at a density of 10 6 cells per dish and grown overnight. Transfections were carried out as described previously (6) . pRNH209 and pRNH255 were included in some transfections at a one-to threefold molar excess relative to pRNH195c or pRNH220c. In the latter experiments, the amount of DNA transfected was kept constant by adjusting the concentration of pUC19 carrier DNA. CAT activity was assayed as described by Seed and Sheen (37) . pRSV␤gal was cotransfected as an internal control for transfection efficiency. The formation of 4-methylumbelliferone from the substrate, 4-methylumbelliferyl ␤-galactopyranoside, was used to determine ␤-galactosidase activity in each of the extracts by fluorometry (2) . Protein concentration was measured by the bicinchoninic acid protein assay (39) . CAT activity was corrected for transfection efficiency (␤-galactosidase activity) and protein content. One-way analysis of variance (Tukey's post test) was performed with the Instat software package (GraphPad). A P value less than 0.05 was accepted as significant.
RESULTS
Previous studies in our laboratory established that a single, specific HepG2 nuclear protein complex forms with the NRE 105 probe (Ϫ833 to Ϫ728) and that the palindrome at Ϫ784 was critical for activity (6) . To determine whether the Ϫ784 palindrome was sufficient for specific binding or whether the flanking guanine and cytosine sequences were also necessary, EMSA analysis was performed with NRE21 and NRE57 as probes (see Materials and Methods). When NRE21 was used as the probe, a single specific DNA-protein complex was observed (Fig. 1A) . Competition with a 10-to 20-fold molar excess of unlabeled NRE21 or NRE 105 decreased specific binding to the radiolabeled NRE21 probe. However, unlabeled NRE57 did not compete for this nuclear protein complex, even at a 100-fold molar excess (Fig. 1A) . The DNA-protein complexes observed with the radiolabeled NRE57 probe do not represent specific binding, since competition did not occur even with a 100-fold molar excess of unlabeled NRE 105 , NRE21, or NRE57 (Fig. 1B) . These results suggest that the NRE palindrome alone is sufficient to form specific complexes with proteins found in HepG2 nuclear extract and that the guanine-and cytosine-rich sequences, in the absence of the palindrome sequence, are incapable of forming specific DNAprotein complexes.
To corroborate the above observation in intact cells, we performed cotransfection competition experiments in HepG2 cells ( Fig. 2A and B) . Cotransfection of a threefold molar excess of a vector containing either a single copy of the NRE Ϫ784 palindrome (pRNH209) or both guanine-and cytosinerich sequences minus the palindrome (pRNH255) had no significant effect on SV40 enhancer-or HSV tk promoter-di-VOL. 15, 1995 NEGATIVE CONTROL OF HUMAN CYP1A1 EXPRESSION 5145 rected CAT expression (pRNH195c). Similar to what has been reported previously (6) , the insertion of NRE 105 immediately upstream of the SV40 enhancer and HSV tk promoter (pRNH220c) down-regulated CAT expression by approximately 70%. Cotransfection of pRNH220c with increasing concentrations of pRNH209 reversed the ability of NRE 105 to down-regulate CAT expression ( Fig. 2A) . In contrast, cotransfection with increasing concentrations of pRNH255 had no significant effect (Fig. 2B ). These data are consistent with the protein-binding studies described earlier. The NRE palindrome alone is capable of competing for cellular factors necessary for the observed transcriptional repression activity of NRE 105 , but the guanine-and cytosine-rich elements minus the palindrome are not. To better understand the observed DNA-protein interactions, point mutations and insertions were introduced into the NRE Ϫ784 palindrome, and competitive EMSA were performed (Fig. 3) . For these assays, DNA fragments containing specific mutations were used to compete with radiolabeled wild-type probes for specific protein binding. Mutant fragments were used at a 5-to 1,000-fold molar excess over the wild-type fragment. As expected, fragments with substitutions at critical guanine residues identified by methylation interference (6) competed poorly with the wild-type probe for specific nuclear protein binding. At a 500-fold molar excess of PAL1 (Ϫ787 guanine to thymidine) and PAL4 (Ϫ787 guanine to thymidine and Ϫ781 cytosine to adenine), the wild-type DNAprotein complexes still retained 100% of their specific radioactivity. This is in contrast to the 12% of specific radioactivity remaining after competition with a 500-fold molar excess of an unlabeled wild-type fragment. Lengthening the 5-bp spacer by 2 bp (PAL7) also abolished the ability to compete with the wild-type probe for specific protein binding. The point mutation introduced in PAL3 (Ϫ781 cytosine to adenine) resulted in a diminished ability to compete. Point mutations in the spacer sequence (PAL5, Ϫ786 cytosine to adenine) or at position Ϫ788 (PAL16, thymidine to cytosine) also resulted in a more intermediate level of competition, with 53 and 41% of the specific radioactivity, respectively, remaining in the wildtype DNA-protein complex after the addition of a 500-fold molar excess of competing fragment. In contrast, the cytosine to adenine substitution at Ϫ789 in PAL13 had little effect; the PAL13 fragment competed as well as the wild-type fragment. To determine whether loss of specific protein binding would correlate with loss of negative regulatory activity, a fragment containing the PAL1 point mutation (Ϫ787 guanine to thymidine) was substituted for the wild-type NRE fragment in the heterologous enhancer-promoter reporter gene construct. When examined in a transient-expression assay, this point mutation resulted in a complete loss of negative regulatory activity (Fig. 4) .
As a first approach to identifying the CYP1A1 NRE-binding The difference in expression of CAT activity observed between pRNH220c (NRE 105 ) and the parent construct pRNH195c (195c) is highly significant (P ϭ 0.0001). Relative to pRNH220c (220c), differences in CAT activity were observed with a one-(ϩ), two-(ϩϩ), or threefold (ϩϩϩ) molar excess of pRNH209 (209), with P values of 0.0013, 0.0028, and 0.31, respectively (A). CAT activity observed after cotransfection of pRNH220c with a threefold molar excess of the guanine-and cytosine-rich elements minus the NRE palindrome (pRNH255) (255) was not significantly different (P ϭ 0.12) from that of pRNH220c alone (B). Cotransfection with either pRNH209 (A) or pRNH255 (B) with the control plasmid (pRNH195c) had no significant effect (P ϭ 0.18 and 0.38, respectively). CAT activity is expressed as counts per minute per hour per unit of ␤-galactosidase activity per milligram of protein and represents the mean Ϯ standard deviation (n ϭ 3 or 4). (Fig. 6 ). Not shown, the FGF-4 NF-Y oligonucleotide also was able to compete with the CYP1A1 NRE Ϫ573 palindrome (6) for specific protein binding. A mutated NF-Y oligonucleotide (Fig. 5 ) failed to compete when used at a 200-fold molar excess over that of the NRE 105 probe.
The NRE Ϫ784 palindrome also shows homology with several other transcription factor consensus sequences, particularly NF1-CTF, CREB, and Oct-1 (Fig. 5 ). We were particularly interested in Oct-1 and AP1, as these transcription factors reportedly bind a rat CYP1A1 NRE (40, 41). However, oligonucleotides representing these consensus sequences were unable to compete even at concentrations as high as a 1,000-fold molar excess over that of the NRE 105 probe (Fig. 7) . Given the competition observed with the NF-Y oligonucleotide in the experiments above, we hypothesized that one or more of the NF-Y transcription factor peptides is involved in the CYP1A1 NRE palindrome-nuclear protein complex. NF-Y consists of three subunits, NF-Y A , NF-Y B , and NF-Y C . All three subunits appear necessary for DNA binding activity, although the NF-Y C subunit is normally tightly associated with the NF-Y A subunit and copurifies with it (14, 23) . Antibodies to the NF-Y A and NF-Y B subunits (25) were preincubated with nuclear extract prepared from HepG2 cells. The pretreated extract was used in EMSA binding reactions with radiolabeled NRE 105 . A monoclonal antibody to NF-Y A as well as an affinity-purified antibody to NF-Y B had no effect on the specific NRE 105 -nuclear protein complex (Fig. 8) . In contrast, pretreatment with the original polyclonal NF-Y B antiserum, from which the affinity-purified antibody was prepared, produced both a diminution in the specific NRE 105 -nuclear protein complex and a second DNA-protein complex with further retarded mobility (Fig. 8) . Incubation with preimmune rabbit serum did not alter the NRE 105 -nuclear protein complexes (Fig. 8, right panel) . FIG. 3 . NRE Ϫ784 palindrome point mutations compete poorly for specific nuclear protein binding as measured by competitive EMSA. Both the wild-type (WT) and mutated NRE palindrome sequences are shown to the right of the graph. Substituted bases are indicated by boldface letters above the wild-type bases they replaced. PAL7 has a 2-bp insertion. The inserted bases are shown in boldface above the spaces where they were introduced. EMSA were performed in the presence of a 0-to 1,000-fold molar excess of wild-type or mutated NRE palindrome fragments. Specific protein complexes formed with the wild-type probe were excised from the gels, and the amount of radioactivity in each slice was determined (Materials and Methods). Data are presented as a percentage of radioactive counts per minute contained within the specific complex (B) in the absence of competitor DNA. 
DISCUSSION
The regulation of human CYP1A1 transcription involves the coordination of several cis-DNA sequence elements and their cognate trans-acting factors (16) . Several early studies implicated an NRE and cognate repressor as one of the factors involved in CYP1A1 regulation (15, 17, 18) . More recently, our group identified two palindromic sequences centered at Ϫ784 and Ϫ573 that act as highly specific recognition sites for nuclear proteins present in human HepG2 cells and that function as transcriptional silencers. On the basis of preliminary studies with the Ϫ784 NRE, the palindrome appeared necessary but not sufficient for optimum activity. Highly conserved guanine and cytosine sequences that flank the palindrome and also exhibit a DNase I protection pattern were hypothesized as ancillary elements. Having no activity on their own, they did enhance the negative regulatory activity of the palindromic sequence, perhaps by stabilizing DNA-protein interactions (6) . In this study, this hypothesis was corroborated by both in vitro DNA binding studies and cotransfection competition experiments in intact cells ( Fig. 1 and 2 ). Other observations also are consistent with this hypothesis. First, the appearance of DNase I hypersensitive sites at residues located between the palindrome and guanine-and cytosine-rich elements are dependent upon protein binding to the latter (6), consistent with stabilization through a change in DNA conformation. Second, if protein binding on both elements were relatively stable, one would expect to observe multiple DNA-protein complexes in an EMSA. However, only a single complex is observed with the intact CYP1A1 NRE.
It is well recognized that interactions between DNA-binding proteins and their recognition sites often depend on specific sequences and sometimes on the spacial orientation of two or more sequences. Site-directed mutagenesis was used in this study to examine the importance of individual bases within and spacing between the Ϫ784 palindrome half-sites (Fig. 3 ). These data demonstrate that binding of HepG2 nuclear protein is dependent upon the integrity of specific DNA residues within both the NRE Ϫ784 palindrome half-sites as well as on the spacing separating the half-sites. These observations also are consistent with previously reported methylation-interference experiments (6) . Most important, we have demonstrated that a point mutation resulting in the loss of specific DNA-protein interaction also results in a loss of negative regulatory function (Fig. 4) . Studies are under way to more thoroughly examine the effect of these mutations within the context of other human CYP1A1 regulatory sequences.
As a first approach towards identifying potential transcription factors that may bind to the CYP1A1 NRE, competition with consensus transcription factor binding sequences showing homology with the NRE Ϫ784 palindrome was evaluated. We hypothesized that one of these factors might be a component of the human CYP1A1 repressor, albeit with modifications or heteromeric associations that result in a high degree of specificity for the NRE palindromic sequence, resulting in a negative rather than positive trans-regulatory function. Effective competition was observed with an oligonucleotide representing the NF-Y CCAAT-box binding factor recognition sequence present in the FGF-4 (hst) promoter (13) (Fig. 6) . The decision to use this probe was spurred by the observation of considerable sequence identity between the NRE Ϫ784 palindrome and the FGF-4 NF-Y site. This includes the 5-bp spacer separating the NRE palindrome half-sites (a CCAAT-box sequence) as well as critical flanking sequences in each half-site. In addition, EMSA and UV cross-linking data presented for the FGF-4 NF-Y site (13) show some resemblance to our own observations of nuclear protein binding to the CYP1A1 NRE Ϫ784 palindrome (4). We were also able to detect considerable sequence homology between the NRE palindrome and/or one of its half-sites and the consensus recognition sequences for FIG. 5 . Sequence comparison of some of the consensus oligonucleotides used in competitive EMSA experiments (Fig. 6 and 7) . Sequences correspond to several synthetic consensus oligonucleotides in which sequence similarities with the NRE Ϫ784 palindrome are apparent. The oligonucleotides are aligned with the 21-bp CYP1A1 NRE Ϫ784 palindrome (NRE6) which is shown entirely in boldface type. The boldface letters present in the transcription factor consensus oligonucleotides several other transcription factors (Fig. 5) . Despite this homology, competition was not observed with the nuclear proteins that bind the CYP1A1 NRE (Fig. 7) . Thus, it is unlikely that any of the cognate DNA binding proteins specific for these other sequences participate in the negative regulation of the human CYP1A1 gene. This includes Oct-1 and AP1, implicated in the negative regulation of the orthologous rat gene (40, 41) , as well as several other CCAAT-box binding factors.
Cross-reactivity with NF-Y A and NF-Y B antibodies was used to confirm the presence or absence of NF-Y in the CYP1A1 NRE complex (Fig. 8) . Three different antibody preparations previously shown to supershift and/or block NF-Y binding to Y-box sequences in both the major histocompatibility complex class II (25) and FGF-4 (13) genes were tested. However, only the polyclonal rabbit serum to NF-Y B reacted with the CYP1A1 NRE-protein complex, resulting in a diminution of the specific complex and a faint band indicative of a supershift. The latter result is similar to that of the reaction observed with authentic NF-Y sites (13, 25) . Combined with the competitive binding observed with the FGF-4 Y-box sequence, these data lead us to conclude that the CYP1A1 NRE-protein complex involves neither NF-Y A nor NF-Y B but a protein immunologically related to the latter.
Several other differences between the binding characteristics of NF-Y to its prototypical recognition sequence and those of the nuclear proteins binding to the CYP1A1 NRE Ϫ784 palindrome support the involvement of an NF-Y B -related but not identical protein. First, the role of specific DNA residues in protein binding differs. For example, when EMSA are performed with fragments in which the residues flanking the CCAAT-box spacer of the NRE Ϫ784 palindrome are mutated (PAL1 and PAL3, Fig. 3 ), no specific binding is observed (5) . In contrast, similar experiments with the NF-Y prototypical recognition sequence, the E␣ oligonucleotide, result in specific complex formation at a level at least 10% of that observed with the wild-type sequence (9) . Second, the methylation-interference pattern for the FGF-4 promoter Y box is distinct from that observed for the CYP1A1 NRE (6, 9, 13). Third, three NF-Y subunits (A, B, and C) must be present to generate the DNA-binding form of this transcription factor (23) . Thus, the addition of the purified subunits to the binding solution is required to generate any observable binding to an NF-Y DNA fragment in Southwestern blot analyses. In contrast, a binding was observed in a Southwestern blot with HepG2 nuclear extract and a CYP1A1 NRE fragment without the addition of proteins to the binding solution (4) . Finally, we have previously demonstrated the presence of a second functional NRE palindrome at Ϫ573 (6). The FGF-4 Y-box oligonucleotide is able to compete with both the NRE Ϫ784 and Ϫ573 palindromic sequences for specific protein binding (5, 6) . However, the Ϫ573 palindrome does not contain the CCAAT-box sequence. It does contain a well-conserved upstream half-site and a lesswell-conserved downstream half-site relative to the NRE Ϫ784 palindrome (see reference 6 for a more complete comparison of these sequences). In contrast to what is observed for authentic NF-Y, this observation suggests the CCAAT box is not critical for specific protein binding to the CYP1A1 NRE.
Given our evidence for the involvement of an NF-Y B -related protein in the transcriptional repression of CYP1A1, we examined the literature for previous reports on negative-acting transcription factors belonging to this family of proteins. Skalnik et al. (38) have described a CCAAT displacement protein (CDP) that competes with NF-Y for binding to regulatory CCAAT box sequences in the gp91-phox gene, thereby preventing NF-Y-dependent gene activation. However, we do not feel that CDP and the CYP1A1 NRE-binding factor are related. Several models have been proposed for transcriptional repression, including competition, squelching, blocking of trans activation, and silencing (35) . We have previously presented evidence that the CYP1A1 NRE and its cognate repressor act as a silencer, but not through a squelching mechanism or the competitive binding mechanism reported for CDP (6) . Consistent with this earlier conclusion, there is no evidence from either our laboratory or others that positive trans-acting factors compete for binding at the CYP1A1 NRE. Further, we consistently observed a single DNA-protein complex by EMSA. Differences (38) , whereas the CYP1A1 NRE binding factor appears to be a multisubunit protein, with individual units ranging between 50 and 100 kDa (4). The suggestion that an NF-Y B -related protein is critical for CYP1A1 NRE-dependent transcriptional repression did cause some concern regarding our heterologous expression experiments involving the HSV tk promoter. Chodosh et al. (7) have identified a low-affinity, but functional, NF-Y binding site in this promoter. One could hypothesize that the ability of the CYP1A1 NRE to down-regulate this promoter (6) might be due to the squelching of the trans-acting proteins necessary for HSV tk promoter activity. However, the NF-Y site from the HSV tk promoter was unable to compete with the CYP1A1 NRE 105 probe for specific protein binding, even at a 500-fold molar excess. Similarly, when the HSV tk promoter fragment was used as a probe, a 1,000-fold excess of the CYP1A1 NRE 105 fragment was unable to compete (5) .
Although the Ah receptor is clearly necessary for the normal activation of CYP1A1 transcription in response to polyaromatic hydrocarbon and halogenated hydrocarbon exposure, our studies have implicated an NRE and cognate trans-acting factor as also being important in modulating the expression of this gene. The latter regulatory mechanism may well be involved in the abnormal constitutive expression of this gene observed in several neoplastic human tumors and tumor-derived cell lines (26, 27, 29, 34) . It may also play a role in the highly inducible CYP1A1 phenotype observed in the human population (22, 32) . In this study, we have examined the CYP1A1 NRE function, as well as nuclear protein binding. The role of specific DNA elements and residues within these elements has been resolved. We also present evidence for the involvement of a protein immunologically related to NF-Y B in the CYP1A1 NRE-protein complex. Although Skalnik et al. (38) have described a CCAAT-box displacement protein capable of repressing NF-Y-regulated genes, to our knowledge our studies represent the first evidence for an NF-Y-related protein involved in transcriptional repression through a noncompetitive mechanism. Further identification and characterization of this protein and others involved in the CYP1A1 NREprotein complex will be critical to our understanding of this regulatory mechanism and, in turn, the role of CYP1A1 in chemical carcinogenesis and toxicity.
